Conv. Plasma
Nigella Sativa

Meta analysis
Home COVID-19 treatment researchBamlanivimab/etesevimabBamlaniv../e.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Bamlanivimab/etesevimab for COVID-19
21 studies from 275 scientists
35,320 patients in 1 country
Statistically significant lower risk for mortality, hospitalization, recovery, cases, and viral clearance.
16 studies from 14 independent teams (all from the same country) show significant improvements.
Efficacy is variant dependent.
COVID-19 Bamlanivimab/etesevimab studies. Jul 2024.
0 0.5 1 1.5+ All studies 47% With exclusions 50% Mortality 54% Hospitalization 42% Recovery 11% Cases 57% Viral clearance 38% RCTs 39% RCT mortality 58% Prophylaxis 57% Early 52% Late 29% Favorsbamlanivimab/e.. Favorscontrol
Home   Post   Share   @CovidAnalysis   Meta AnalysisMeta   Efficacy is highly variant dependent. In Vitro studies suggest a lack of efficacy for omicron Haars, Liu, Pochtovyi, Sheward, VanBlargan. mAb use may create new variants that spread globally Focosi, Leducq, and may be associated with prolonged viral loads, clinical deterioration, and immune escape Choudhary, Günther, Leducq. Bamlanivimab/etesevimab was adopted in 7 countries. Submit updates/corrections. Summary.
Jul 23
Covid Analysis Bamlanivimab/etesevimab for COVID-19: real-time meta analysis of 21 studies
Statistically significant lower risk is seen for mortality, hospitalization, recovery, cases, and viral clearance. 16 studies from 14 independent teams (all from the same country) show significant improvements. Meta analysis using the mos..
Mar 30
Hattab et al., Infection, doi:10.1007/s15010-024-02223-y SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants
Review of SARS-CoV-2 variants showing increased transmissibility, disease severity, and immune escape with mutations in the spike protein receptor binding domain. Authors cover variants from the initial D614G mutation through omicron sub-..
Jan 26
Wilcock et al., JAMA Health Forum, doi:10.1001/jamahealthforum.2023.5044 Clinical Risk and Outpatient Therapy Utilization for COVID-19 in the Medicare Population
Analysis of Medicare beneficiaries in 2022 showing that outpatient COVID-19 treatments like antivirals and monoclonal antibodies were disproportionately used by patients at lower risk of severe infection and outcomes. Retrospective studie..
Jan 7
Günther et al., medRxiv, doi:10.1101/2024.01.06.24300890 Variant-specific humoral immune response to SARS-CoV-2 escape mutants arising in clinically severe, prolonged infection
Report on a prolonged SARS-CoV-2 infection in an immunocompromised patient treated with bamlanivimab, where bamlanivimab escape variant S:S494P emerged. Later, the onset of an endogenous IgM antibody response coincided with the appearance..
Sep 28
Pochtovyi et al., Vaccines, doi:10.3390/vaccines11101533 In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
In Vitro study showing sharply reduced neutralization of SARS-CoV-2 variants XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1 with monoclonal antibodies cilgavimab, tixagevimab, imdevimab, etsevimab, casirivim..
Sep 27
Haars et al., Microorganisms, doi:10.3390/microorganisms11102417 Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023
Analysis of 7,950 SARS-CoV-2 samples from central Sweden collected between March 2022 and May 2023 tracking the prevalence of omicron sublineages and mutations in the spike protein conferring resistance to monoclonal antibodies over time...
Aug 10
Focosi et al., Drug Resistance Updates, doi:10.1016/j.drup.2023.100991 Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment
Review of reports of treatment-emergent resistance to COVID-19 monoclonal antibodies (mAbs), showing that some post-mAb treatment mutations appeared to spread globally soon after the mAb was introduced, raising concerns about transmission..
Jun 10
Wade et al., Value in Health, doi:10.1016/j.jval.2023.03.2056 Variation in Demographic Characteristics, Socioeconomic Status, Clinical Presentation and Selected Treatments in Mortality Among Patients with a Diagnosis of COVID-19 in the United States
Retrospective analysis of mortality for COVID-19 patients in the USA. Authors do not provide adjusted results, preventing any strong evidence. However it is notable that, despite comparable treatment frequencies, the mortality for patient..
Apr 4
Kip et al., Annals of Internal Medicine, doi:10.7326/M22-1286 Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19
15% lower combined mortality/hospitalization (p=0.54). Retrospective 2,571 patients treated with mAbs in the USA, and 5,135 control patients, showing lower combined mortality/hospitalization for bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, sotrovimab, and bebtelovimab, with s..
Oct 15
Nagler et al., American Journal of Health-System Pharmacy, doi:10.1093/ajhp/zxac295 The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study
61% higher mortality (p=0.4), 51% higher ICU admission (p=0.5), 49% lower hospitalization (p<0.0001), and 39% lower progression (p<0.0001). PSM retrospective 1,344 patients in the USA, showing lower hospitalization with monoclonal antibody treatment. Authors combine patients treated with bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab.
Aug 22
Chew et al., Nature Communications, doi:10.1038/s41467-022-32551-2 Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
25% lower hospitalization (p=0.6), 14% slower recovery (p=0.97), 1% higher progression (p=1), and 26% improved viral clearance (p=0.002). RCT 317 outpatients in the USA showing faster viral load and inflammatory biomarker decline, but no significant differences in clinical outcomes.
Jul 31
Fivelstad et al., International Journal of Scientific Research, 11:7 Bamlanivimab as monotherapy for high-risk COVID-19 patients with mild to moderate symptoms
63% lower hospitalization (p=0.0006). Retrospective 335 outpatients with mild to moderate COVID-19 and at least one high-risk comorbidity, showing significantly lower hospitalization with bamlanivimab treatment compared to the control group.
Mar 31
Wilden et al., Journal of the National Comprehensive Cancer Network, doi:10.6004/jnccn.2021.7309 Real World Outcomes of Cancer Patients With SARS-CoV-2 Infection Receiving Monoclonal Antibodies
51% lower hospitalization (p=0.06). Retrospective 395 patients in the USA receiving casirivimab/imdevimab or bamlanivimab, showing lower risk of hospitalization with treatment, statistically significant for casirivimab/imdevimab.
Mar 12
Dougan et al., medRxiv, doi:10.1101/2022.03.10.22272100 Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19
12% faster recovery and 9% improved viral clearance (p<0.0001). RCT showing improved viral clearance with bamlanivimab/etesevimab combined with bebtelovimab. Results refer to the placebo controlled portion of the trial.
Feb 16
Zhou et al., bioRxiv, doi:10.1101/2022.02.15.480166 SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies
In Vitro study showing that omicron BA.2 evades all monoclonal antibodies tested, including sotrovimab and tixagevimab/cilgavimab which retained activity for omicron BA.1.
Feb 9
Dale et al., Journal of the American Geriatrics Society, doi:10.1111/jgs.17705 Clinical Outcomes of Monoclonal Antibody Therapy During a COVID-19 Outbreak in a Skilled Nursing Facility - Arizona, 2021
89% lower mortality (p=0.01) and 86% lower progression (p=0.002). Retrospective 75 COVID+ patients in a skilled nursing facility in the USA, 56 treated within a median of 2 days from symptom onset with bamlanivimab, showing significantly lower mortality with treatment.
Jan 27
Delasobera et al., Infectious Diseases in Clinical Practice, doi:10.1097/IPC.0000000000001109 Impact of Rapidly Deployed COVID-19 Monoclonal Antibody Infusion Clinics on Rate of Hospitalization
52% lower hospitalization (p=0.01) and 20% lower progression (p=0.52). Retrospective 438 patients in the USA, 253 treated with bamlanivimab, showing significantly lower hospitalization with treatment.
Jan 27
Priest et al., Infectious Diseases in Clinical Practice, doi:10.1097/IPC.0000000000001130 Bamlanivimab for the Prevention of Hospitalizations and Emergency Department Visits in SARS-CoV-2–Positive Patients in a Regional Health Care System
no change in mortality (p=1), 4% higher hospitalization (p=0.86), and 5% more combined hospitalization/ER visits (p=0.86). Retrospective 379 bamlanivimab patients and 379 matched controls in the USA, showing no significant differences with treatment.
Dec 20
Sheward et al., bioRxiv, doi:10.1101/2021.12.19.473354 Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)
In Vitro study showing that omicron is substantially resistant to neutralization by monoclonal antibodies REGN10933, REGN10987, Ly-CoV016 and Ly-CoV555. S309 (the parent of Sotrovimab) had only 2-fold loss in potency.
Dec 17
VanBlargan et al., bioRxiv, doi:10.1101/2021.12.15.472828 An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies
In vitro study (Vero-TMPRSS2 and Vero-hACE2-TMPRSS2) showing complete loss of inhibitory activity for B.1.1.529 omicron with LY-CoV555, LY-CoV016, REGN10933, REGN10987, and CT-P59, ~12-fold decrease for COV2-2196/COV2-2130, and minimal ch..
Dec 15
Liu et al., bioRxiv, doi:10.1101/2021.12.14.472719 Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2
In Vitro study (Vero-E6-TMPRSS2) showing 18 of 19 monoclonal antibodies were no longer effective or significantly impaired with B.1.1.529 omicron.
Nov 19
Leavitt et al., Cureus, doi:10.7759/cureus.19747 Real World Utilization of Bamlanivimab at a Rural Community Hospital
30% lower hospitalization (p=0.6) and 42% improvement (p=0.04). Retrospective 136 outpatients showing bamlanivimab reduced emergency department visits at 28 days, but not hospitalizations, compared to a control group prior to authoritzation in patients with mild to moderate COVID-19.
Nov 3
Rubin et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab546 Bamlanivimab efficacy in older and high BMI outpatients with Covid-19 selected for treatment in a lottery-based allocation process
65% lower hospitalization (p=0.04). Retrospective database analysis of 1257 PCR+ outpatients with age ≥65, BMI≥35, 191 receiving bamlanivimab via lottery. Authors note that the alpha variant was most common during the study period, and that efficacy against other variants c..
Nov 2
Kaleta et al., Research Square, doi:10.21203/ Antibody escape and global spread of SARS-CoV-2 lineage A.27
Anaysis of antibody escape showing variant A.27 completely escaped neutralization with LY-COV555 and partially with REGN10987. B.1.617.2 escaped these antibodies in a similar manner, suggesting that L452R facilitates the escape. Authors n..
Oct 29
Schiaroli et al., Mediterranean Journal of Hematology and Infectious Diseases, doi:10.4084/MJHID.2021.061 Early Treatment with BamlanivimabAlone does not Prevent COVID-19 Hospitalization and Its Post-Acute Sequelae. A Real Experience in Umbria, Italy
Retrospective 39 patients treated with bamlanivimab in Italy, showing results far below expectations based on the BLAZE1 trial. Authors note that most patients had the alpha variant which does not have the E484K and L452R mutations known ..
Oct 8
Cooper et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab512 Real-world Assessment of 2,879 COVID-19 Patients Treated with Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study
7% higher mortality (p=0.86), 17% lower ICU admission (p=0.51), and 24% lower hospitalization (p=0.0005). Retrospective 2,879 patients and matched controls in the USA, showing significantly lower mortality and hospitalization with monoclonal antibody treatment (bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab). There was signif..
Oct 7
Dougan et al., New England Journal of Medicine, doi:10.1056/NEJMoa2102685 Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
95% lower mortality (p=0.002), 70% lower combined mortality/hospitalization (p=0.0002), 11% faster recovery (p=0.007), and 67% improved viral clearance (p<0.0001). Results from the BLAZE-1 RCT of combined bamlanivimab/etesevimab, showing significantly lower mortality and combined mortality/hospitalization with treatment. NCT04427501.
Oct 1
Ganesh et al., Journal of Clinical Investigation, doi:10.1172/JCI151697 Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19
74% lower mortality (p=0.11), 49% lower ICU admission (p=0.1), and 37% lower hospitalization (p=0.01). Retrospective 2,335 bamlanivimab patients and 2,335 PSM controls in the USA, showing significantly lower hospitalization with treatment.
Sep 15
Choudhary et al., medRxiv, doi:10.1101/2021.09.03.21263105 Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy
Analysis of ACTIV-2/A5401, showing the potential for rapid emergence of resistance during monoclonal antibody treatment, resulting in prolonged high level viral loads and clinical worsening. Treatment-emergent resistance mutations were mo..
Jun 23
Webb et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab331 Real-World Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients with Early COVID-19
80% lower mortality (p=0.09), 53% lower hospitalization (p<0.0001), and 27% fewer combined hospitalization/ER visits (p<0.0001). Retrospective 479 patients treated with bamlanivimab showing lower mortality, hospital admission, and emergency department visits with treatment. Authors incorrectly state that "no other COVID-19 therapies for ambulatory patients hav..
Jun 10
Corwin et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab305 The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting
80% lower mortality (p=0.08) and 39% lower hospitalization (p=0.0004). Retrospective 780 bamlanivimab patients and 5,337 patients not receiving treatment, showing lower hospitalization and ER visits with treatment.
May 18
Focosi et al., Research Square, doi:10.21203/ Emergence of SARS-CoV-2 Spike Escape Mutation Q493r After Bamlanivimab/Etesevimab Treatment for COVID-19
Case study showing that a mutation resistant to both bamlanivimab and etesevimab can arise in vivo. Authors note that accelerated evolution can occur under selective pressure from therapeutic interventions with neutralizing antibodies, an..
May 16
Karr et al., Military Medicine, doi:10.1093/milmed/usab188 Bamlanivimab Use in a Military Treatment Facility
62% fewer combined hospitalization/ER visits (p=0.22). Retrospective 40 outpatients showing improvement in symptoms and lower risk of hospitalization/ER visits with bamlanivimab, without statistical significance. Different counts for hospitalization are provided in the abstract and text: &quo..
May 10
Alam et al., Cureus, doi:10.7759/cureus.14933 Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study
75% lower mortality (p=0.03) and 65% lower hospitalization (p=0.08). Retrospective 246 nursing home patients showing lower mortality with early bamlanivimab treatment.
Mar 30
Bariola et al., medRxiv, doi:10.1101/2021.03.25.21254322 Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection
67% lower mortality (p=0.05), 64% lower combined mortality/hospitalization (p=0.0003), and 61% lower hospitalization (p=0.001). Retrospective 234 patients receiving bamlanivimab and 234 matched controls, showing lower hospitalization and mortality with treatment. Greater benefit was seen with administration within 4 days of their positive COVID-19 test.
Jan 21
Lilly, Press Release Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
57% fewer symptomatic cases (p=0.0002). Press release on the BLAZE-2 trial at nursing homes showing significantly lower symptomatic COVID-19 with treatment.
Jan 21
Gottlieb et al., JAMA, doi:10.1001/jama.2021.0202 Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
71% fewer combined hospitalization/ER visits (p=0.05). RCT for LY-CoV555 monotherapy and LY-CoV555/LY-CoV016 combination therapy with 592 patients showing lower hospitalization/ER visits with treatment. For viral load at day 11, a statistically significant reduction was found with combination..
Dec 22
ACTIV-3/TICO LY-CoV555 study group, NEJM, doi:10.1056/NEJMoa2033130 A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
100% higher mortality (p=0.22). Late stage RCT of LY-CoV555 added to remdesivir, showing non-statistically significant higher mortality with the addition of LY-CoV555.
Oct 28
Chen et al., NEJM, doi:10.1056/NEJMoa2029849 SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
74% lower hospitalization (p=0.02). Interim analysis of the BLAZE-1 phase 2 trial of outpatients showing lower hospitalization or ER visits (1.6% versus 6.3%), and improvements in symptoms and viral load compared to placebo. NCT04427501.
Oct 26
Lilly, Press Release Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial
ACTIV-3 intermin analysis shows LY-CoV555 is unlikely to help hospitalized patients. ACTIV-2, BLAZE-1 and BLAZE-2 trials remain ongoing.
Oct 7
Lilly, Press Release SARS-CoV-2 neutralizing antibody program update
84% fewer combined hospitalization/ER visits (p=0.05). Interim results from the BLAZE-1 outpatient RCT showing improvements in viral load, symptoms and hospitalization. Combination therapy significantly reduced viral load at day 11 (p=0.011). A greater effect is seen at day 7 (p<0.001). The p..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.